86 related articles for article (PubMed ID: 8918488)
21. Totally implantable central venous access ports. Analysis of 700 cases.
Barbetakis N; Asteriou C; Kleontas A; Tsilikas C
J Surg Oncol; 2011 Nov; 104(6):654-6. PubMed ID: 21671465
[TBL] [Abstract][Full Text] [Related]
22. Complications of indwelling venous access devices in cancer patients.
Eastridge BJ; Lefor AT
J Clin Oncol; 1995 Jan; 13(1):233-8. PubMed ID: 7799025
[TBL] [Abstract][Full Text] [Related]
23. Retrospective evaluation of totally implantable venous access port devices: early and late complications.
Gurkan S; Seber S; Gur O; Yetisyigit T; Okan Donbaloglu M; Ozkaramanli Gur D
J BUON; 2015; 20(1):338-45. PubMed ID: 25778336
[TBL] [Abstract][Full Text] [Related]
24. Advances in venous access devices and nursing management strategies.
Wickham RS
Nurs Clin North Am; 1990 Jun; 25(2):345-64. PubMed ID: 2110664
[TBL] [Abstract][Full Text] [Related]
25. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer.
Beckers MM; Ruven HJ; Seldenrijk CA; Prins MH; Biesma DH
Thromb Res; 2010 Apr; 125(4):318-21. PubMed ID: 19640573
[TBL] [Abstract][Full Text] [Related]
26. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.
Kollmannsberger C; Daneshmand S; So A; Chi KN; Murray N; Moore C; Hayes-Lattin B; Nichols C
J Clin Oncol; 2010 Feb; 28(4):537-42. PubMed ID: 20026807
[TBL] [Abstract][Full Text] [Related]
27. Complications associated with 9-10Fr venous access port use in adjuvant intraperitoneal chemotherapy after a cytoreductive surgery in ovarian cancer patients.
Milczek T; Klasa-Mazurkiewicz D; Wydra D
Adv Med Sci; 2015 Sep; 60(2):216-9. PubMed ID: 25863871
[TBL] [Abstract][Full Text] [Related]
28. [Totally implantable venous access ports: frequency of complications and analysis of bacterial contamination after ablation].
Barbut F; Soukouna S; Lalande V; Garcia ML; Neyme D; de Gramont A; Petit JC
Pathol Biol (Paris); 2004 Dec; 52(10):566-74. PubMed ID: 15596304
[TBL] [Abstract][Full Text] [Related]
29. Externalized Groshong catheters and Hickman ports for central venous access in gynecologic oncology patients.
Gleeson NC; Fiorica JV; Mark JE; Pinelli DM; Hoffman MS; Roberts WS; Cavanagh D
Gynecol Oncol; 1993 Dec; 51(3):372-6. PubMed ID: 8112648
[TBL] [Abstract][Full Text] [Related]
30. [Radiological placement of peripheral central venous access ports at the forearm. Technical results and long term outcome in 391 patients].
Lenhart M; Schätzler S; Manke C; Strotzer M; Seitz J; Gmeinwieser J; Völk M; Zorger N; Feuerbach S; Herold T; Paetzel C
Rofo; 2010 Jan; 182(1):20-8. PubMed ID: 19536729
[TBL] [Abstract][Full Text] [Related]
31. The evolution of biofilms in venous access devices implanted in children with Wilms' tumour.
Gregory MA; Hadley GP
Pediatr Surg Int; 1998 Jul; 13(5-6):400-5. PubMed ID: 9639627
[TBL] [Abstract][Full Text] [Related]
32. Surgically implanted subcutaneous venous access devices in cancer patients.
Repelaer van Driel OJ; Kuin CM; van de Velde CJ
Neth J Surg; 1988 Jun; 40(4):97-9. PubMed ID: 3217033
[TBL] [Abstract][Full Text] [Related]
33. Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life.
Bow EJ; Kilpatrick MG; Clinch JJ
J Clin Oncol; 1999 Apr; 17(4):1267. PubMed ID: 10561188
[TBL] [Abstract][Full Text] [Related]
34. Totally implantable central venous catheters of the port-a-cath type: complications due to its use in the treatment of cancer patients.
Granic M; Zdravkovic D; Krstajic S; Kostic S; Simic A; Sarac M; Ivanovic N; Radovanovic D; Dikic S; Kovcin V
J BUON; 2014; 19(3):842-6. PubMed ID: 25261677
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
36. Peripherally placed totally implantable venous-access port systems of the forearm: clinical experience in 763 consecutive patients.
Goltz JP; Scholl A; Ritter CO; Wittenberg G; Hahn D; Kickuth R
Cardiovasc Intervent Radiol; 2010 Dec; 33(6):1159-67. PubMed ID: 20414657
[TBL] [Abstract][Full Text] [Related]
37. Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients.
Piran S; Ngo V; McDiarmid S; Le Gal G; Petrcich W; Carrier M
Thromb Res; 2014 Jan; 133(1):30-3. PubMed ID: 24188799
[TBL] [Abstract][Full Text] [Related]
38. [Complications after implantation of subcutaneous central venous port].
Sakamoto E; Hasegawa H; Komatsu S; Norimizu S; Shingu Y; Inaba K; Taguchi Y; Ito Y; Watanabe M; Arimoto A; Isaji T; Makino A; Miura Y; Santo M
Gan To Kagaku Ryoho; 2013 May; 40(5):613-6. PubMed ID: 23863584
[TBL] [Abstract][Full Text] [Related]
39. Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients.
Fischer L; Knebel P; Schröder S; Bruckner T; Diener MK; Hennes R; Buhl K; Schmied B; Seiler CM
Ann Surg Oncol; 2008 Apr; 15(4):1124-9. PubMed ID: 18214621
[TBL] [Abstract][Full Text] [Related]
40. Polyurethane II catheter as long-indwelling intravenous catheter in patients with cancer.
Volkow P; Vázquez C; Téllez O; Aguilar C; Barrera L; Rodrgíuez E; Vilar-Compte D; Zinser J; Calderón E; Pérez-Padilla JR; Mohar A
Am J Infect Control; 2003 Nov; 31(7):392-6. PubMed ID: 14639434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
